|
WO1998032869A1
(en)
*
|
1997-01-29 |
1998-07-30 |
Neurosearch A/S |
Expression vectors and methods for in vivo expression of therapeutic polypeptides
|
|
JP2004516016A
(ja)
*
|
2000-09-18 |
2004-06-03 |
ジェンザイム・コーポレイション |
ハイブリッドユビキチンプロモーターを含む発現ベクター
|
|
EP1624067A3
(en)
*
|
2000-09-18 |
2006-03-15 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
|
PT1600510E
(pt)
*
|
2001-07-04 |
2007-06-25 |
Chromagenics Bv |
Sequências de adn com actividade anti-repressora.
|
|
US7344886B2
(en)
*
|
2002-11-29 |
2008-03-18 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
|
|
DE10256083A1
(de)
|
2002-11-29 |
2004-08-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
|
|
US7384744B2
(en)
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
|
DE10338531A1
(de)
|
2003-08-19 |
2005-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Reklonierung von Produktionszellen
|
|
US8669109B2
(en)
|
2003-08-19 |
2014-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methods of producing proteins in Chinese hamster ovary (CHO) cells
|
|
US20050101017A1
(en)
*
|
2003-11-10 |
2005-05-12 |
Wojtek Auerbach |
Method of improving gene targeting using a ubiquitin promoter
|
|
GB0509965D0
(en)
*
|
2005-05-17 |
2005-06-22 |
Ml Lab Plc |
Improved expression elements
|
|
US9163257B2
(en)
*
|
2005-06-20 |
2015-10-20 |
Cadila Healthcare Limited |
Expression vector and methods of producing high levels of proteins
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
US20080124760A1
(en)
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
|
RS63930B1
(sr)
|
2011-10-28 |
2023-02-28 |
Prothena Biosciences Ltd |
Humanizovana antitela koja prepoznaju alfa-sinuklein
|
|
DK2807188T3
(da)
|
2012-01-27 |
2019-10-07 |
Prothena Biosciences Ltd |
Humaniserede antistoffer, der genkender alpha-synuclein
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
EP2938726B1
(en)
|
2012-12-31 |
2017-09-27 |
Boehringer Ingelheim International GmbH |
Heterologous intron within a signal peptide
|
|
WO2014102101A1
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Novel intron sequences
|
|
US10501531B2
(en)
|
2013-03-13 |
2019-12-10 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US9989540B2
(en)
|
2013-05-10 |
2018-06-05 |
The Regents Of The University Of California |
Diagnostic and monitoring system for Huntington's disease
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
WO2015004633A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize islet-amyloid polypeptide (iapp)
|
|
US9850302B2
(en)
|
2013-07-12 |
2017-12-26 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
|
JP2017501848A
(ja)
|
2013-11-19 |
2017-01-19 |
プロセナ バイオサイエンシーズ リミテッド |
便秘症状からのレビー小体病の免疫療法のモニター
|
|
DK3089760T3
(da)
|
2013-12-31 |
2020-03-16 |
Proteonic Biotechnology Ip B V |
Konstrukt og sekvens til forbedret genekspression
|
|
JP2017514458A
(ja)
|
2014-03-12 |
2017-06-08 |
プロセナ バイオサイエンシーズ リミテッド |
Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
|
|
KR20160131082A
(ko)
|
2014-03-12 |
2016-11-15 |
프로테나 바이오사이언시즈 리미티드 |
Lg1-3에 특이적인 항-라미닌4 항체
|
|
PT3116911T
(pt)
|
2014-03-12 |
2019-09-04 |
Prothena Biosciences Ltd |
Anticorpos anti-mcam e métodos de utilização associados
|
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
|
|
CA2944402A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
EP3230309B1
(en)
|
2014-12-10 |
2023-03-29 |
OPKO Biologics Ltd. |
Methods of producing long acting ctp-modified growth hormone polypeptides
|
|
TWI786505B
(zh)
|
2015-01-28 |
2022-12-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI769570B
(zh)
|
2015-01-28 |
2022-07-01 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI718121B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
US10881102B2
(en)
|
2015-05-18 |
2021-01-05 |
Zymtronix, Llc |
Magnetically immobilized microbiocidal enzymes
|
|
WO2017011292A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymtronix, Llc |
Automated bionanocatalyst production
|
|
EP3350226A2
(en)
|
2015-09-16 |
2018-07-25 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
PT3452507T
(pt)
|
2016-05-02 |
2022-12-20 |
Prothena Biosciences Ltd |
Imunoterapia anti-tau
|
|
MY198194A
(en)
|
2016-05-02 |
2023-08-09 |
Prothena Biosciences Ltd |
Antibodies Recognizing Tau
|
|
MX2018013386A
(es)
|
2016-05-02 |
2019-02-28 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
WO2018007922A2
(en)
|
2016-07-02 |
2018-01-11 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
JP7016470B2
(ja)
|
2016-07-02 |
2022-02-07 |
プロセナ バイオサイエンシーズ リミテッド |
抗トランスサイレチン抗体
|
|
WO2018007924A2
(en)
|
2016-07-02 |
2018-01-11 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
MY206271A
(en)
|
2016-07-11 |
2024-12-06 |
Opko Biologics Ltd |
Long-acting coagulation factor vii and methods of producing same
|
|
CA3031802A1
(en)
|
2016-08-13 |
2018-02-22 |
Zymtronix Catalytic Systems, Inc. |
Magnetically immobilized biocidal enzymes and biocidal chemicals
|
|
JP2020505025A
(ja)
|
2017-01-13 |
2020-02-20 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
免疫工学的な改変をした多能性細胞
|
|
KR102784294B1
(ko)
|
2017-05-02 |
2025-03-19 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
|
WO2019064053A1
(en)
|
2017-09-28 |
2019-04-04 |
Prothena Biosciences Limited |
DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
|
AU2018345807B2
(en)
|
2017-10-06 |
2025-02-06 |
Novo Nordisk A/S |
Methods of detecting transthyretin
|
|
PE20211453A1
(es)
|
2017-11-29 |
2021-08-05 |
Prothena Biosciences Ltd |
Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
|
|
EP3846938B1
(en)
|
2018-09-05 |
2024-08-07 |
ZYMtronix Catalytic Systems, Inc. |
Immobilized enzymes and microsomes on magnetic scaffolds
|
|
CU24781B1
(es)
|
2018-11-08 |
2026-02-09 |
Prothena Biosciences Ltd |
Anticuerpos humanizados que reconocen tau
|
|
EA202190986A1
(ru)
|
2018-11-26 |
2021-12-14 |
Фоти Севен, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
|
|
JP7630834B2
(ja)
|
2019-03-03 |
2025-02-18 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
US12221622B2
(en)
|
2019-05-10 |
2025-02-11 |
The Regents Of The University Of California |
Modified pluripotent cells
|
|
CA3144621A1
(en)
|
2019-06-26 |
2020-12-30 |
The Regents Of The University Of California |
Sirpalpha-silenced natural killer (nk) cells
|
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
JP7728747B2
(ja)
|
2019-08-23 |
2025-08-25 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ２４発現細胞およびそれらの用途
|
|
WO2021146222A1
(en)
|
2020-01-13 |
2021-07-22 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
|
WO2021146471A2
(en)
|
2020-01-15 |
2021-07-22 |
The Regents Of The University Of California |
Transplanted cell protection via inhibition of polymorphonuclear cells
|
|
KR20220142433A
(ko)
|
2020-01-17 |
2022-10-21 |
사나 바이오테크놀로지, 인크. |
유전자 발현 조절용 안전 스위치
|
|
KR20220158046A
(ko)
|
2020-03-25 |
2022-11-29 |
사나 바이오테크놀로지, 인크. |
신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
|
|
BR112022026508A2
(pt)
|
2020-06-24 |
2023-03-07 |
Prothena Biosciences Ltd |
Anticorpos que reconhecem sortilina
|
|
WO2022036150A1
(en)
|
2020-08-13 |
2022-02-17 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
JP2024501971A
(ja)
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃａｒ－ｔ活性を調節するための方法及び組成物
|
|
BR112023024231A2
(pt)
|
2021-05-19 |
2024-01-30 |
Sana Biotechnology Inc |
Células t primárias rhd negativas hipoimunogênicas
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
KR20240046319A
(ko)
|
2021-07-14 |
2024-04-08 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
|
|
JP2024535677A
(ja)
|
2021-08-11 |
2024-10-02 |
サナ バイオテクノロジー，インコーポレイテッド |
即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
US20240358761A1
(en)
|
2021-08-11 |
2024-10-31 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
EP4479416A1
(en)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
EP4716541A2
(en)
|
2023-05-22 |
2026-04-01 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
TW202530246A
(zh)
|
2023-09-15 |
2025-08-01 |
愛爾蘭商歐賽爾普羅希那有限公司 |
細胞穿透劑及其用途
|
|
AR133834A1
(es)
|
2023-09-15 |
2025-11-05 |
Prothena Biosciences Ltd |
Agentes de penetración célular y sus usos
|
|
WO2025059486A1
(en)
|
2023-09-15 |
2025-03-20 |
Prothena Biosciences Limited |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025059491A2
(en)
|
2023-09-15 |
2025-03-20 |
Prothena Platform Technologies Limited |
Methods, compositions, and kits including cell-penetrating agents
|
|
WO2025166633A2
(en)
|
2024-02-07 |
2025-08-14 |
Westlake Genetech. Ltd. |
Split gene editing systems and uses thereof
|